Fixed-Duration Ibrutinib Plus Venetoclax Earns Approval in Canada for Previously Untreated CLL

Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.

Related Keywords

Canada ,Christine Chen ,Canada Health ,Princess Margaret Cancer Centre ,Health Canada ,Janssen Pharmaceuticals ,Cumulative Illness Rating Scale ,New Orleans ,Chronic Lymphocytic Leukemia ,News ,Global Oncology ,Imbruvica ,Ibrutinib ,Venetoclax ,Venclexta ,Cll ,